Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tsiala Benard"'
Autor:
Chrystelle Girardet, Magali Mathieu, François Vallée, Jacques Le-Roux, Fangxian Sun, Laurence Fabien, Corinne Terrier, Celine Ginesty, Bruno Filoche-Romme, Florence Gruss-Leleu, Maysoun Shomali, Monsif Bouaboula, Sylvie Beccari, Pascal Desmazeau, Gilles Lebourg, Tsiala Benard, Victor Certal, Pascale Vicat, Andrew Hebert, Carlos Garcia-Echeverria, Laurent Schio, Youssef El-Ahmad, Gary Mccort, Claire Muller, Maurice Brollo, Mikhail Levit, Luc Bertin, Hong Cheng, Véronique Loyau, Valerie Steier, Fabienne Thompson, Audrey Louboutin, Fabienne Pilorge, Alexey Rak, Frank Halley, Patrick Richepin, Christelle Perrault, Pierre-Yves Abecassis, Michel Tabart, Albane Courjaud
Publikováno v:
Journal of Medicinal Chemistry. 63:512-528
More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-dependent, but mutations usually confer constitutive ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6b8e31876cd3009f301f509589bd98
https://doi.org/10.1021/acs.jmedchem.9b01293
https://doi.org/10.1021/acs.jmedchem.9b01293
Autor:
Jessica Mestadier, Sandrine Valence, Elisa Francesconi, Conception Nemecek, Mireille Kenigsberg, Celine Lefranc, Véronique Do-Vale, Tsiala Benard, Françoise Bégassat, Fabrice Bonche, Hélène Goulaouic, Loreley Calvet, Jean-Paul Nicolas, Coumaran Egile, Christelle Castell, Christine Delaisi, Anne-Marie Lefebvre
Publikováno v:
Molecular Cancer Therapeutics. 14:384-394
Activation of the MET/HGF pathway is common in human cancer and is thought to promote tumor initiation, metastasis, angiogenesis, and resistance to diverse therapies. We report here the pharmacologic characterization of the triazolopyridazine derivat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0beefff4d1ef21d5059e266e3201cd6
https://doi.org/10.1158/1535-7163.mct-14-0428
https://doi.org/10.1158/1535-7163.mct-14-0428
Autor:
Benoit Pasquier, Youssef El-Ahmad, Bruno Filoche-Rommé, Christine Dureuil, Florence Fassy, Pierre-Yves Abecassis, Magali Mathieu, Thomas Bertrand, Tsiala Benard, Cédric Barrière, Samira El Batti, Jean-Philippe Letallec, Véronique Sonnefraud, Maurice Brollo, Laurence Delbarre, Véronique Loyau, Fabienne Pilorge, Luc Bertin, Patrick Richepin, Jérôme Arigon, Jean-Robert Labrosse, Jacques Clément, Florence Durand, Romain Combet, Pierre Perraut, Vincent Leroy, Frédéric Gay, Dominique Lefrançois, François Bretin, Jean-Pierre Marquette, Nadine Michot, Anne Caron, Christelle Castell, Laurent Schio, Gary McCort, Hélène Goulaouic, Carlos Garcia-Echeverria, Baptiste Ronan
Publikováno v:
Journal of Medicinal Chemistry. 58:376-400
Vps34 (the human class III phosphoinositide 3-kinase) is a lipid kinase involved in vesicle trafficking and autophagy and therefore constitutes an interesting target for cancer treatment. Because of the lack of specific Vps34 kinase inhibitors, we ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f364d6dcf08b486db73cd403e73d3b1
https://doi.org/10.1021/jm5013352
https://doi.org/10.1021/jm5013352
Autor:
Jean Pierre Marquette, Andreas Karlsson, Sylvie Monget, Thomas Bertrand, Jean Christophe Carry, Frank Halley, Marc Antoine Perrin, Jean Paul Nicolas, Tsiala Benard, Angela Virone-Oddos, Luc Bertin, Céline Amara, Hélène Bonnevaux, Laurence Delbarre, Gilles Doerflinger, Pierre Yves Abecassis, Youssef El-Ahmad, Véronique Charrier, Victor Certal, Bruno Filoche-Romme, Florence Gruss-Leleu, Sébastien Perron, Alexey Rak, Patrick Richepin, Stephane Guerif, Carlos Garcia-Echeverria, Loic Vincent, Nadine Michot, Magali Mathieu, Véronique Loyau, Olivier Lemaitre, Maurice Brollo, Christoph Lengauer, Houlfa Guizani, Laurent Schio, Fabienne Thompson, Cécile Delorme
Publikováno v:
Journal of Medicinal Chemistry. 57:903-920
Compelling molecular biology publications have reported the implication of phosphoinositide kinase PI3Kβ in PTEN-deficient cell line growth and proliferation. These findings supported a scientific rationale for the development of PI3Kβ-specific inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c85553ea8c69d86eeaefddb3c7297b6
https://doi.org/10.1021/jm401642q
https://doi.org/10.1021/jm401642q
Autor:
Jean Christophe Carry, Youssef El-Ahmad, Bruno Filoche-Romme, Frank Halley, Loic Vincent, Andreas Karlsson, Thomas Bertrand, Christoph Lengauer, Tsiala Benard, Pierre Yves Abecassis, Peter Below, Alexey Rak, Jean Paul Nicolas, Gilles Lebourg, Audrey Louboutin, Victor Certal, Laurent Schio, Cécile Delorme, Nadine Michot, Fabienne Pilorge, Fabienne Chatreaux, Pascale Lejeune, Fabienne Thompson, Angela Virone-Oddos, Isabelle Vade, Hélène Bonnevaux, Jean Pierre Marquette, Odile Angouillant-Boniface
Publikováno v:
Journal of Medicinal Chemistry. 55:4788-4805
Most of the phosphoinositide-3 kinase (PI3K) kinase inhibitors currently in clinical trials for cancer treatment exhibit pan PI3K isoform profiles. Single PI3K isoforms differentially control tumorigenesis, and PI3Kβ has emerged as the isoform invol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da44cb5e3b90d40fe34a0bb8a89c84d
https://doi.org/10.1021/jm300241b
https://doi.org/10.1021/jm300241b
Autor:
Véronique Do-Vale, Fabrice Bonche, Tsiala Benard, Mireille Kenigsberg, Jean-Paul Nicolas, Coumaran Egile, Christoph Lengauer, Jessica Mestadier, Conception Nemecek, Françoise Bégassat, Loreley Calvet, Hélène Goulaouic, Christine Delaisi
Publikováno v:
Cancer Research. 72:845-845
SAR125844 is a potent MET kinase inhibitor for intravenous (IV) administration, with nanomolar activity against the wild-type enzyme (IC50 = 4.2 nM) and some kinase domain mutants, such as M1250T and Y1235D. It is highly selective for MET kinase in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e43d804e12437d8ab2c8b48d1936840a
https://doi.org/10.1158/1538-7445.am2012-845
https://doi.org/10.1158/1538-7445.am2012-845
Autor:
Cécile Delorme, Hélène Bonnevaux, Jean-Paul Nicolas, Christoph Lengauer, Joerg Bussenius, Fabienne Thompson, Paul Foster, Laurent Debussche, Franck Halley, Angela Virone-Oddos, Andreas Karlsson, David J. Matthews, Jean-Christophe Carry, Tsiala Benard, Pascale Lejeune, Pierre-Yves Abecassis, Oliver Raeber, Laurent Schio, Jing Wang, Renaud Morales, Victor Certal, Lam Nguyen, Kenneth D. Rice, Ron Aoyama, Chris Jaeger, Nadine Michot, Torsten Trowe
Publikováno v:
Cancer Research. 70:4475-4475
Abnormal PI3K pathway activation plays a major role in cancer, as a result of either RTK activation or somatic mutations of major components of the pathway, including activating point mutations and amplification of the PIK3CA gene as well as loss of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44bde52ddc69b542ab2be70d1d212923
https://doi.org/10.1158/1538-7445.am10-4475
https://doi.org/10.1158/1538-7445.am10-4475